Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infanrix hexa versus Vaxelis in infants on a 2-, 4-, and 12-month schedule
2019-002988-10Phase 4Completed
- Sponsor
- GSK
- Start
- Aug 2020
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of pertussis filamentous haemagglutinin and DTaP-IPV-Hep B-PRP-T vaccine in Haemophilus influenzae type b disease (Hib), diphtheria, Tetanus and 3 more (2 arms), sponsored by GSK. Primary endpoints: Anti-PRP antibody concentrations at Month 11, Post-booster anti-PRP geometric mean concentrations and 1 more. Started Aug 2020; status: completed.
02
Drugs
pertussis filamentous haemagglutininDTaP-IPV-Hep B-PRP-T vaccine
03
Conditions
Haemophilus influenzae type b disease (Hib)diphtheriaTetanuspertussishepatitis B (HBV)
Beyond the preview
Go deeper on 2019-002988-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002988-10.